Andres Forero-Torres MD

Hematology•Birmingham, AL

Professor, Medicine, University of Alabama School of Medicine

Join to View Full Profile

619 19th St SBirmingham, AL 35249
Phone+1 205-934-6600

Summary

Director, Clinical Studies Shared Facility Comprehensive Cancer Center

Education & Training

University of Alabama Medical CenterFellowship, Hematology and Medical Oncology, 1988 - 1991
Pontifical Xavierian UniversityClass of 1982

Certifications & Licensure

AL State Medical License 2001 - 2025

Awards, Honors, & Recognition

America's Top Doctors Castle Connolly, 2010-2014
America's Top Doctors for Cancer Castle Connolly, 2009-2013
Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012
Most Compassionate Doctor American Registry
Join now to see all

Clinical Trials

BMS-247550 in Treating Patients With Metastatic Colorectal Cancer Start of enrollment: 2002 Feb 01
Terminated
Phase 2
Radiolabeled Monoclonal Antibody in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma Start of enrollment: 2001 Aug 01
Terminated
Phase 1
Open Label Trial for Post-Menopausal Women With Newly Diagnosed Operable Breast Cancer Start of enrollment: 2005 Jun 01
Completed
Phase 2
Safety and Efficacy Study of an Anti-CD20 Monoclonal Antibody (AME-133v) to Treat Non-Hodgkin's Lymphoma Start of enrollment: 2006 Jul 01
Completed
Phase 1
Forodesine in the Treatment of Cutaneous T-Cell Lymphoma Start of enrollment: 2007 Jul 01
Completed
Phase 2
Safety Study of ²¹²Pb-TCMC-Trastuzumab Radio Immunotherapy Start of enrollment: 2011 Jul 01
Completed
Phase 1
A Study of Brentuximab Vedotin in Relapsed or Refractory Non-Hodgkin Lymphoma Start of enrollment: 2011 Aug 01
Completed
Phase 2
Open-label, Phase II, Study of Everolimus Plus Letrozole in Postmenopausal Women With ER+, HER2- Metastatic or Locally Advanced Breast Cancer Start of enrollment: 2013 Mar 07
Completed
Phase 2
A Study of Brentuximab Vedotin With Hodgkin Lymphoma (HL) and CD30-expressing Peripheral T-cell Lymphoma (PTCL) Start of enrollment: 2012 Oct 31
Completed
Phase 2
ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas Start of enrollment: 2013 Jan 31
Completed
Phase 3
A Safety Study of SGN-CD19A for B-Cell Lymphoma Start of enrollment: 2013 Feb 01
Completed
Phase 1
Study to Evaluate Efficacy, Safety, Tolerability, and Pharmacodynamics of Entospletinib in Adults With Relapsed or Refractory Hematologic Malignancies Start of enrollment: 2013 Mar 14
Terminated
Phase 2
Study of Brentuximab Vedotin Combined With Bendamustine in Patients With Hodgkin Lymphoma Start of enrollment: 2013 Jun 01
Completed
Phase 1, Phase 2
A Pharmacodynamics Pre-surgical Study of LEE011 in Early Breast Cancer Patients (MONALEESA-1) Start of enrollment: 2013 Oct 01
Terminated
Phase 2
Paclitaxel and BKM120 Before Surgery in Treating Patients With Stage II or III Estrogen Receptor-Positive and HER2-Negative Breast Cancer Start of enrollment: 2014 Aug 01
Withdrawn
Phase 2
A Safety Study of SGN-LIV1A in Breast Cancer Patients Start of enrollment: 2013 Oct 22
Completed
Phase 1
Open-label, Phase II Study of Stomatitis Prevention With a Steroid-based Mouthwash in Post-menopausal Women With Estrogen-receptor-positive (ER+), Human Epidermal Growth Factor Receptor 2 (HER2)- Metastatic or Locally Advanced Breast Cancer Start of enrollment: 2014 May 01
Completed
Phase 2
Study of LEE011 With Fulvestrant and BYL719 or BKM120 in Advanced Breast Cancer Start of enrollment: 2014 May 19
Completed
Phase 1
A Safety Study of SGN-CD19B in Patients With B-cell Non-Hodgkin Lymphoma Start of enrollment: 2016 Feb 01
Terminated
Phase 1
Brentuximab Vedotin and Nivolumab in Treating Patients With Early Stage Classic Hodgkin Lymphoma Start of enrollment: 2018 Nov 28
ACTIVE_NOT_RECRUITING
PHASE2
Join now to see all

Publications & Presentations

PubMed

8 citations
Adjuvant Trastuzumab Emtansine Versus Paclitaxel Plus Trastuzumab for Stage I Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: 5-Year Results and Corre...
Paolo Tarantino, Nabihah Tayob, Guillermo Villacampa, Chau Dang, Denise A Yardley
Journal of Clinical Oncology. 2024-11-01
4 citations
Neoadjuvant Trebananib plus Paclitaxel-based Chemotherapy for Stage II/III Breast Cancer in the Adaptively Randomized I-SPY2 Trial-Efficacy and Biomarker Discovery.
Kathy S Albain, Christina Yau, Emanuel F Petricoin, Denise M Wolf, Julie E Lang
Clinical Cancer Research. 2024-02-16
4 citations
Race, Gene Expression Signatures, and Clinical Outcomes of Patients With High-Risk Early Breast Cancer.
Beverly Kyalwazi, Christina Yau, Michael J Campbell, Toshio F Yoshimatsu, A Jo Chien
JAMA Network Open. 2023-12-01

Abstracts/Posters

Brentuximab Vedotin with Chemotherapy for Stage 3/4 Classical Hodgkin Lymphoma (cHL): 4-Year Update of the Echelon-1 Study
Andres Forero-Torres, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Lectures

A Phase 1b Study Investigating the Combination of the Tetravalent Bispecific NK Cell Engager AFM13 and Pembrolizumab in Patients with Relapsed/Refractory Hodgkin Lymph...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Phase Ib study of gedatolisib in combination with palbociclib and endocrine therapy (ET) in women with estrogen receptor (ER) positive (+) metastatic breast cancer (MB...
2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018

Press Mentions

Older Patients with Hodgkin Lymphoma Benefit from Treatment with Brentuximab VedotinOctober 7th, 2015
PI3Kδ and JAK1 Inhibitors Show Promise in Advanced Hodgkin LymphomaJune 19th, 2015